SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

The purpose of this study was to evaluate the activity of the indolinone kinase inhibitor SU11248 against the receptor tyrosine kinase KIT in vitro and in vivo, examine the role of KIT in small cell lung cancer (SCLC), and anticipate clinical utility of SU11248 in SCLC. SU11248 is an oral, multitargeted tyrosine kinase inhibitor with direct antitumor and antiangiogenic activity through targeting platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor, KIT, and FLT3 receptors. Treatment of the KIT-expressing SCLC-derived NCI-H526 cell line in vitro with SU11248 resulted in dose-dependent inhibition of stem cell factor-stimulated KIT phosphotyrosine levels and proliferation. The biological significance of KIT inhibition was evaluated in vivo by treating mice bearing s.c. NCI-H526 tumors with SU11248 or another structurally unrelated KIT inhibitor, STI571 (Gleevec), which is also known to inhibit Bcr-Abl and PDGFRbeta. SU11248 treatment resulted in significant tumor growth inhibition, whereas inhibition from STI571 treatment was less dramatic. Both compounds reduced phospho-KIT levels in NCI-H526 tumors, with a greater reduction by SU11248, correlating with efficacy. Likewise, phospho-PDGFRbeta levels contributed by tumor stroma and with known involvement in angiogenesis were strongly inhibited by SU11248 and less so by STI571. Because platinum-based chemotherapy is part of the standard of care for SCLC, SU11248 was combined with cisplatin, and significant tumor growth delay was measured compared with either agent alone. These results expand the profile of SU11248 as a KIT signaling inhibitor and suggest that SU11248 may have clinical potential in the treatment of SCLC via direct antitumor activity mediated via KIT as well as tumor angiogenesis via vascular endothelial growth factor receptor FLK1/KDR and PDGFRbeta.

[1]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[2]  John F. Murray,et al.  Textbook of Respiratory Medicine , 1988 .

[3]  T Takahashi,et al.  Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. , 1991, Oncogene.

[4]  P. Carlson,et al.  c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. , 1993, Cancer research.

[5]  T. Nakamura,et al.  Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. , 1993, British Journal of Cancer.

[6]  S. Lev,et al.  Steel factor and c-kit protooncogene: genetic lessons in signal transduction. , 1994, Critical reviews in oncogenesis.

[7]  G. Kalemkerian.  Biology of lung cancer. , 1994, Current opinion in oncology.

[8]  R. Stahel,et al.  Biology of lung cancer. , 1994, Lung cancer.

[9]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. , 1995, International archives of allergy and immunology.

[10]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[11]  G. Krystal,et al.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.

[12]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[13]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[14]  J. Litz,et al.  Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. , 1997, Cancer research.

[15]  Leflunomide approved for rheumatoid arthritis; other drugs nearing approval. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[16]  H. Joensuu,et al.  High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer , 1998, International journal of cancer.

[17]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[18]  E. Buchdunger,et al.  In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.

[19]  M. Oursler,et al.  Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. , 1999, Cancer research.

[20]  R. Salgia,et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.

[21]  S. Honsawek,et al.  The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  M. Arock,et al.  c‐Kit and c‐kit mutations in mastocytosis and other hematological diseases , 2000, Journal of leukocyte biology.

[23]  J. Cherrington,et al.  New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. , 2000, Advances in cancer research.

[24]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[25]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[26]  R. Ilaria,et al.  Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. , 2001, Blood.

[27]  J. Schiller,et al.  Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer , 2001, Oncology.

[28]  S. Honsawek,et al.  Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. , 2001, Cancer research.

[29]  P. D. Dal Cin,et al.  Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. , 2001, Cancer research.

[30]  C. Angeletti,et al.  Small cell lung carcinoma (SCLC): the angiogenic phenomenon. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[31]  W. Schwenk,et al.  Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron‐specific enolase or lactate dehydrogenase , 2002, Respirology.

[32]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[33]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.